{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:10:50Z","timestamp":1794978650838,"version":"4.9.1"},"reference-count":20,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,8]]},"DOI":"10.1182\/bloodadvances.2026020518","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:18:08Z","timestamp":1783531088000},"page":"5934-5937","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["<i>TNFRSF17<\/i>\n                    genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0616-8694","authenticated-orcid":false,"given":"Benjamin","family":"Podvin","sequence":"first","affiliation":[{"name":"1Laboratory of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France"},{"name":"2Tumor Persistence and Immune Response in Hematological Malignancies Laboratory, Interdisciplinary Cancer Research Center of Lille, University of Lille, INSERM U1366, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Lee","sequence":"additional","affiliation":[{"name":"3Hematology Department, Arthur Child Comprehensive Cancer Center, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Tilmont","sequence":"additional","affiliation":[{"name":"2Tumor Persistence and Immune Response in Hematological Malignancies Laboratory, Interdisciplinary Cancer Research Center of Lille, University of Lille, INSERM U1366, Lille, France"},{"name":"4Hematology Department, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauthier","family":"Decool","sequence":"additional","affiliation":[{"name":"1Laboratory of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4836-7237","authenticated-orcid":false,"given":"Doriane","family":"Cavalieri","sequence":"additional","affiliation":[{"name":"4Hematology Department, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Demarquette","sequence":"additional","affiliation":[{"name":"5Hematology Department, Dunkerque Hospital, Dunkerque, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Gower","sequence":"additional","affiliation":[{"name":"4Hematology Department, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Nudel","sequence":"additional","affiliation":[{"name":"4Hematology Department, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Bourgeois","sequence":"additional","affiliation":[{"name":"6Hematology Department, Groupe Hospitalier de l\u2019Institut Catholique Lillois, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3893-0464","authenticated-orcid":false,"given":"Daniela","family":"Robu","sequence":"additional","affiliation":[{"name":"7Hematology Department, Lens Hospital, Lens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Tricot","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Valenciennes Hospital, Valenciennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e8s","family":"Arib","sequence":"additional","affiliation":[{"name":"4Hematology Department, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Cacheux","sequence":"additional","affiliation":[{"name":"4Hematology Department, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Caillault-Venet","sequence":"additional","affiliation":[{"name":"1Laboratory of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-9546","authenticated-orcid":false,"given":"Claude","family":"Preudhomme","sequence":"additional","affiliation":[{"name":"1Laboratory of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France"},{"name":"2Tumor Persistence and Immune Response in Hematological Malignancies Laboratory, Interdisciplinary Cancer Research Center of Lille, University of Lille, INSERM U1366, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3927-1022","authenticated-orcid":false,"given":"Nicolas","family":"Duployez","sequence":"additional","affiliation":[{"name":"1Laboratory of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France"},{"name":"2Tumor Persistence and Immune Response in Hematological Malignancies Laboratory, Interdisciplinary Cancer Research Center of Lille, University of Lille, INSERM U1366, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[{"name":"4Hematology Department, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Neri","sequence":"additional","affiliation":[{"name":"3Hematology Department, Arthur Child Comprehensive Cancer Center, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Bahlis","sequence":"additional","affiliation":[{"name":"3Hematology Department, Arthur Child Comprehensive Cancer Center, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7653-711X","authenticated-orcid":false,"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[{"name":"2Tumor Persistence and Immune Response in Hematological Malignancies Laboratory, Interdisciplinary Cancer Research Center of Lille, University of Lille, INSERM U1366, Lille, France"},{"name":"4Hematology Department, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"2","key":"2026090810513265100_bib1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2026090810513265100_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med"},{"issue":"5","key":"2026090810513265100_bib3","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"2026090810513265100_bib4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"2026090810513265100_bib5","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"2026090810513265100_bib6","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026090810513265100_bib7","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"25","key":"2026090810513265100_bib8","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026090810513265100_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"2026090810513265100_bib10","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"2026090810513265100_bib11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.2023023557","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","volume":"144","author":"Firestone","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026090810513265100_bib12","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1158\/2643-3230.BCD-25-0005","article-title":"Timing genomic antigen loss in multiple myeloma treated with T cell-redirecting immunotherapies","volume":"6","author":"Papadimitriou","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"24","key":"2026090810513265100_bib13","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026090810513265100_bib14","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood-2025-1030","article-title":"Antigen-dependent clonal sweep with sequential or combinatory anti-myeloma T cell engagers","volume":"146","author":"Lee","year":"2025","journal-title":"Blood"},{"issue":"9","key":"2026090810513265100_bib15","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"2026090810513265100_bib16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2643-3230.BCD-24-0118","article-title":"Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed\/refractory multiple myeloma","volume":"6","author":"Fandrei","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2026090810513265100_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2514752","article-title":"Dual targeting of extramedullary myeloma with talquetamab and teclistamab","volume":"394","author":"Kumar","year":"2026","journal-title":"N Engl J Med"},{"issue":"13","key":"2026090810513265100_bib18","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.2023022499","article-title":"BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms","volume":"143","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"25","key":"2026090810513265100_bib19","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.2024026212","article-title":"Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2026090810513265100_bib20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41375-026-02889-3","article-title":"The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D","volume":"40","author":"Riedhammer","year":"2026","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5934\/2541817\/blooda_adv-2026-020518-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5934\/2541817\/blooda_adv-2026-020518-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:51:40Z","timestamp":1788879100000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/17\/5934\/569593\/TNFRSF17-genomic-profiling-guides-retreatment-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":20,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020518","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,8]]},"published":{"date-parts":[[2026,8,28]]}}}